Canditral Contraindications

Congestive Heart Failure: ITRACONAZOLE Capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. (See Warnings and Pharmacology: Pharmacokinetics: Special Populations under Actions.)
Drug Interactions: Co-administration of a number of CYP3A4 substrates are contraindicated with ITRACONAZOLE.
Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin and, in subjects with renal or hepatic impairment, colchicine. This increase in drug concentrations caused by co-administration with itraconazole may increase or prolong both the pharmacologic effect and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia.
ITRACONAZOLE should not be administered for the treatment of onychomycosis to pregnant patients or to women contemplating pregnancy.
ITRACONAZOLE is contraindicated for patients who have shown hypersensitivity to itraconazole.
There is limited information regarding cross-hypersensitivity between itraconazole and other azole antifungal agents. Caution should be used when prescribing ITRACONAZOLE to patients with hypersensitivity to other azoles.